A small, multicenter study examined whether a single dose of individualized CAR T-cell therapy could improve mobility in people with Stiff Person Syndrome (SPS). At 16 weeks, participants showed an overall improvement in a walking test, alongside reports of meaningful gains in daily function. The findings are preliminary: the study included 26 patients, had no randomized control group, and does not establish whether the benefits will last.
What did the study find?
At 16 weeks after treatment, participants improved overall on a walking test covering approximately 7.6 meters. Researchers also reported steady walking patterns and improvements in balance measures. These changes may matter because SPS can make walking, maintaining balance, and performing everyday activities difficult.
Some participants described practical changes in their lives. One person who had relied heavily on family support for walking and basic needs was able to return to work after treatment. Individual experiences illustrate possible benefits, but they cannot show how often similar outcomes might occur across a larger patient population.
How was the CAR T-cell treatment given?
Each of the 26 participants received one dose of a personalized CAR T-cell therapy. The treatment was designed to target B cells involved in autoimmune activity and antibody production. Before the infusion, the clinical team used preparation and monitoring protocols intended to manage treatment risks.
Researchers assessed participants at weeks 4, 8, 12, and 16. Follow-up included neurological examinations, walking and balance tests, blood and immune-system measurements, and monitoring for complications. The study also tracked autoantibody levels and blood-cell counts.
What is Stiff Person Syndrome?
Stiff Person Syndrome is a rare neurological disorder marked by muscle stiffness and painful spasms. Sudden sounds, light touch, or other stimuli can trigger symptoms. Many cases involve autoimmune activity, including antibodies against glutamic acid decarboxylase (GAD), although the underlying biology is not fully understood.
Stiffness and spasms can interfere with movement, balance, walking, and everyday tasks. The severity varies, and some people continue to experience substantial symptoms despite existing treatments.
Why are researchers studying CAR T-cell therapy for SPS?
CAR T-cell therapy is being investigated as a way to alter immune cells that contribute to autoimmune disease. In SPS, the approach aims to reduce B cells involved in antibody production and, in turn, lessen harmful immune activity. The study’s walking-test results offer an early indication that this strategy may be associated with functional improvement.
The findings may also inform research into other autoimmune neurological conditions. However, the results do not yet show that CAR T-cell therapy is an established or broadly suitable treatment for SPS.
What side effects and safety risks were reported?
The study monitored infusion-related reactions, symptoms associated with cytokine release syndrome, changes in blood counts, and infections. The reported short-term effects included mild-to-moderate cytokine release symptoms and temporary blood-count changes. Serious adverse events were described as limited and managed under the study protocols.
CAR T-cell treatment can carry risks that require specialist supervision. Continued monitoring is important because infection, blood-related complications, immune effects, and neurological symptoms may need attention during follow-up.
How long might the benefits last?
The 16-week results do not answer whether improvements will persist over the long term. Researchers need to follow participants for longer and repeat functional and immune assessments to determine whether symptoms return, benefits remain stable, or immune activity changes over time.
The study’s follow-up schedule included assessments through week 16. Longer studies could add evaluations at six months and beyond, but the results described here do not establish a definitive long-term monitoring schedule.
What are the study’s limitations?
- Small cohort: The study included 26 participants, so its results may not represent the wider SPS population.
- No randomized control group: The design cannot determine with confidence how much of the change resulted from treatment rather than other factors.
- Short follow-up: The reported 16-week findings do not establish durability or long-term safety.
- Uncertain patient selection: Larger studies are needed to identify which patients may be most likely to benefit.
What research is needed next?
Researchers need larger, controlled studies to test whether CAR T-cell therapy improves mobility and other symptoms compared with appropriate alternatives. Future research should also assess the duration of benefits, optimize treatment protocols, track long-term safety, and investigate whether biological markers can help predict who is most likely to respond.
The study was reported in JAMA Neurology. Its early results are notable, but further clinical research is needed before doctors can determine the treatment’s effectiveness and role in SPS care.
Be the first to comment